Publication | Open Access
IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
12
Citations
22
References
2022
Year
Biomedical EngineeringTumor BiologyOncologyCancer DetectionAnti-cancer AgentRadiation OncologyCancer ResearchHealth SciencesUnsuitable MeasurePreclinical ModelsTumor TargetingProstatic DiseasePharmacologyLncap SpheroidsUrologyDrug Sensitivity EvaluationDrug DiscoveryMedicineSpheroids FormationHigh-throughput Screening
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50 curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
| Year | Citations | |
|---|---|---|
Page 1
Page 1